Personally I am not a fan of Aspirin. It is a cox-1 inhibitor which prevents the creation of prostaglandins. Hence I am not particularly surprised by this.
chatGPT:
Tidy transcript
Chapter 1 — Aspirin’s initial success
In 2010, Oxford neurologist Peter Rothwell published a Lancet analysis that reshaped medical thinking about aspirin. By analysing eight randomised trials involving more than 25,000 patients, his team reported that daily aspirin reduced long-term cancer mortality, with the apparent benefit becoming stronger after several years of use. Cancer Research UK’s contemporary summary described an approximately 20% lower risk of cancer death overall, around one-third lower risk after more than five years, and particularly strong signals for gastrointestinal cancers. (Cancer Research UK - Cancer News)
By 2016, the US Preventive Services Task Force recommended low-dose aspirin for some adults aged 50–59 at increased cardiovascular risk, explicitly including colorectal cancer prevention as part of the expected benefit. The recommendation did not apply to people already at high colorectal-cancer risk, who were told to consult their clinician. (USPSTF)
The video stresses an important distinction: it is discussing primary prevention—people taking aspirin without a previous heart attack, stroke, stent, or similar cardiovascular event. Aspirin for secondary prevention is a separate issue and should not be stopped without medical advice.
The first clue that aspirin might protect against cancer came from observational studies. In 1988, a Melbourne case-control study suggested that people with colorectal cancer were less likely to have used aspirin than healthy controls. Over the next two decades, many observational studies pointed in the same direction. But observational evidence cannot prove that aspirin itself caused the lower cancer risk; aspirin users may differ from non-users in many other ways.
Chapter 2 — Aspirin and cancer: the Rothwell era
Rothwell’s contribution was to look inside older cardiovascular aspirin trials and extract cancer outcomes. These trials had not been designed primarily as cancer-prevention trials, but they were randomised, which made them more persuasive than observational studies.
His 2010 analysis reported reduced cancer mortality, especially after several years. Later 2012 Lancet papers strengthened the picture, suggesting reductions in metastasis and longer-term cancer mortality. This created a powerful narrative: aspirin was cheap, familiar, and might protect not just the heart but also against cancer.
Chapter 3 — John McNeil’s concern
John McNeil, an epidemiologist at Monash University, was uneasy about how far the findings were being extrapolated. The Rothwell evidence came mostly from trials designed for heart and stroke outcomes, not cancer. Many participants were middle-aged rather than elderly, some trials used higher doses, and some apparent cancer benefits emerged only after very long follow-up, sometimes using cancer registries after the original trials had ended.
Meanwhile, the people actually taking aspirin for cancer prevention were often older adults taking low-dose aspirin—around 100 mg daily. McNeil saw a major change in practice based on evidence that had not directly tested that population.
Chapter 4 — The ASPREE trial
McNeil and colleagues therefore ran ASPREE: Aspirin in Reducing Events in the Elderly. It enrolled 19,114 community-dwelling older adults—generally aged 70 or above, or 65 and above for some US minority participants—without cardiovascular disease, dementia, or major physical disability. Participants were randomised to 100 mg aspirin daily or placebo. (JAMA Network)
After a median trial treatment period of about 4.7 years, ASPREE found that aspirin did not prevent first cardiovascular events in this older primary-prevention population. More surprisingly, aspirin was associated with more cancer-related deaths during the randomised phase, the opposite of what the earlier cancer-prevention story would have predicted. The investigators themselves treated this cautiously, because perhaps the follow-up was too short to see delayed cancer prevention.
Chapter 5 — Longer ASPREE follow-up
The extended ASPREE follow-up, published in JAMA Oncology in 2026, followed participants for a median of 8.6 years. It included 3,448 incident cancers and 1,173 cancer-related deaths. Low-dose aspirin was not associated with lower overall cancer incidence and was not associated with lower colorectal cancer incidence; for colorectal cancer, the hazard ratio was 1.01, essentially no difference. But aspirin exposure was associated with increased cancer-related mortality overall, HR 1.15. (JAMA Network)
The extended analysis also found that the excess cancer mortality seen during the active trial phase did not persist as a “legacy effect” after the trial drug stopped. That is important: it suggests no continuing post-treatment cancer harm from the original randomisation, but it does not remove the concern about risk during active use in older adults. (JAMA Network)
Chapter 6 — Cochrane’s updated view
The video then turns to a 2026 Cochrane review. Cochrane reported that 10 randomised trials involving 124,837 participants found aspirin probably does not reduce bowel cancer risk in the first 5–15 years of use. Possible benefits after more than 10–15 years were seen in some studies, but the certainty of that evidence was very low, partly because much of it came from observational post-trial follow-up. (Cochrane)
Cochrane also emphasised immediate harms: daily aspirin increases serious extracranial bleeding risk and probably increases haemorrhagic stroke risk. Older adults and people with ulcers or bleeding disorders are especially vulnerable. (Cochrane)
The USPSTF had already changed course in 2022. It now recommends individualised decision-making only for adults aged 40–59 with at least 10% 10-year cardiovascular risk, and recommends against initiating aspirin for primary prevention in adults aged 60 or older. The USPSTF also states that evidence is unclear on whether aspirin reduces colorectal cancer incidence or mortality. (USPSTF)
Chapter 7 — Mechanistic puzzle
The video says the clinical results are puzzling because mechanistic work still makes aspirin look biologically plausible as an anti-metastatic drug. A 2025 Nature paper reported that COX-1 inhibitors including aspirin can enhance anti-metastatic immunity by reducing platelet-derived thromboxane A₂, thereby releasing T cells from an immunosuppressive pathway involving ARHGEF1. (Nature)
The video proposes possible explanations for the mismatch between mechanism and ASPREE:
First, immune ageing may matter. Releasing the “brake” on T cells may help young, vigorous immune systems but have less benefit in older immune systems.
Second, aspirin might mask early inflammatory symptoms of cancer, delaying diagnosis, though the video says the ASPREE researchers considered this less likely.
Third, chronic suppression of inflammation might, in some contexts, impair cancer surveillance or containment in older adults.
The video’s point is not that the mechanism is false, but that a plausible mechanism in mice or younger systems does not guarantee net benefit in elderly humans.
Chapter 8 — Lynch syndrome and precision prevention
The video then notes an important exception: Lynch syndrome. In the CAPP2 trial, people with Lynch syndrome were randomised to 600 mg aspirin daily or placebo. The 10-year follow-up in The Lancet reported a protective effect against colorectal cancer in this genetically high-risk group. (The Lancet)
This means the aspirin-cancer story is not simply “aspirin works” or “aspirin does not work.” The more precise interpretation is: aspirin may prevent cancer in selected groups, at specific doses, ages, durations, and risk profiles, but that does not justify routine low-dose aspirin for cancer prevention in healthy older adults.
Chapter 9 — Practical conclusion
The video ends with practical advice:
People taking aspirin after a heart attack, stroke, stent, or other cardiovascular event should not stop it based on this cancer-prevention discussion. That is secondary prevention.
For healthy older adults taking aspirin “just in case” or for cancer prevention, the rationale has weakened substantially. For adults over 60, the USPSTF recommends against starting aspirin for primary prevention, and both ASPREE and Cochrane undermine the older colorectal-cancer-prevention argument. (JAMA Network)
For Lynch syndrome or other high-risk settings, aspirin may still be beneficial, but that should be handled through specialist medical advice.
Summary
The video describes a major reversal in the aspirin-prevention story. In the 2010s, analyses led by Peter Rothwell suggested that daily aspirin reduced long-term cancer deaths, especially gastrointestinal cancer deaths, and this helped support guideline recommendations that included colorectal cancer prevention. But the later ASPREE trial directly tested low-dose aspirin in healthy older adults and found no reduction in cancer incidence, no colorectal-cancer benefit, and a signal of increased cancer mortality during active use. The 2026 ASPREE follow-up found no long-term cancer-incidence benefit and continued concern about cancer mortality during aspirin exposure. (JAMA Network)
The broader evidence has also shifted. Cochrane’s 2026 review found little or no colorectal-cancer prevention benefit in the first 5–15 years, uncertain very-long-term benefit, and clearer bleeding risks. The USPSTF no longer recommends aspirin for colorectal-cancer prevention in the general primary-prevention population and recommends against starting aspirin for primary prevention in adults aged 60 or older. (Cochrane)
The video’s central message is that aspirin is not a universal cancer-prevention pill. It may help selected groups—especially Lynch syndrome carriers—but routine use in healthy older adults for cancer prevention is no longer supported.
What is good about the video
The video correctly distinguishes primary from secondary prevention. That is crucial, because the evidence for aspirin after a cardiovascular event is much stronger than the evidence for aspirin in people with no such history.
It also gives a fair historical arc: observational studies, Rothwell’s influential post-hoc trial analyses, guideline adoption, then reversal after ASPREE and updated systematic reviews. That is a useful example of how medical recommendations can change when evidence moves from indirect or secondary analyses to more directly relevant trials.
The video is particularly strong on effect modification: age, dose, baseline cancer risk, bleeding risk, immune function, and duration of exposure all matter. The Lynch syndrome section is important because it prevents an over-simple conclusion that “aspirin never prevents cancer.”
It also handles mechanistic evidence sensibly. The Cambridge/Nature mechanism is interesting and biologically plausible, but the video correctly treats it as insufficient to override human outcome data in older adults.
Critique and caveats
The phrase “the people on aspirin started dying first” is dramatic and may overstate the certainty of causation. ASPREE found an association under randomisation during active treatment, which is concerning, but the mechanism remains unresolved. The extended follow-up also found no continuing “legacy” cancer-mortality effect after stopping aspirin. That weakens any simplistic claim that aspirin permanently accelerates cancer. (JAMA Network)
The video sometimes implies that ASPREE is the decisive final answer. It is decisive for healthy older adults starting low-dose aspirin, but not for younger adults, high cardiovascular-risk adults, Lynch syndrome carriers, people with previous colorectal cancer, or biomarker-defined cancer subgroups. Those are different questions.
The discussion of immunosenescence and inflammation is plausible but speculative. It is reasonable hypothesis-generation, not established explanation. The strongest evidence is clinical: no cancer-incidence benefit in older adults and increased bleeding risk. The mechanistic explanation for higher cancer mortality remains uncertain.
The Cochrane section would benefit from more nuance. Cochrane’s conclusion is not simply “aspirin increases colorectal cancer mortality”; rather, it found little or no reliable colorectal-cancer prevention in the first 5–15 years, possible but very uncertain longer-term benefit, and clearer bleeding harms. The video’s “77% higher colorectal cancer mortality” claim may be drawn from a subgroup/time-window analysis, but without showing the confidence intervals and certainty grading, it risks sounding firmer than Cochrane’s own cautious conclusion. Cochrane explicitly describes the long-term benefit evidence as very low certainty and stresses bleeding harms as clearer. (Cochrane)
The video also underplays absolute risk. Relative figures such as 15% increased cancer mortality or 59% increased serious bleeding sound large, but clinical decisions depend on absolute baseline risk. For an individual, the absolute benefit or harm depends heavily on age, prior ulcer/bleeding history, cardiovascular risk, cancer risk, and concurrent medications.
Finally, the video’s practical advice is broadly right but should be framed medically: people should not start or stop daily aspirin without discussing it with a clinician, especially if they may be taking it for secondary prevention or have high cardiovascular risk.
Bottom line
The video’s main conclusion is well supported: daily low-dose aspirin should not be treated as a general cancer-prevention strategy for healthy older adults. The earlier cancer-prevention story was built on suggestive but indirect evidence; ASPREE and later reviews make the case much weaker for older primary-prevention users.
The best current interpretation is precision prevention, not blanket prevention: aspirin may still have a role in Lynch syndrome, selected cardiovascular-risk patients, and possibly genetically or molecularly defined cancer contexts, but routine “just in case” aspirin for older adults has a poor risk-benefit profile.